Giloralimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.

**Synonyms:** - ABBV-927 - Agonistic Anti-CD40 Monoclonal Antibody ABBV-927 - Anti-CD40 Agonist Monoclonal Antibody ABBV-927 - Anti-CD40 Monoclonal Antibody ABBV-927 - GILORALIMAB - PR-1614645